d3-2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester | 526203-26-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: d3-2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester
• 英文别名: 1-Methyl-3-propyl-1H-pyrazole-5-carboxylic Acid Ethyl Ester-d3；ethyl 5-propyl-2-(trideuteriomethyl)pyrazole-3-carboxylate
• CAS: 526203-26-9
• 化学式: C₁₀H₁₆N₂O₂
• 分子量: 199.225
• InChiKey: ZPSRHLWRTVNGSM-HPRDVNIFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  d3-2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester 在 sodium hydroxide 、 水 、 盐酸 作用下， 反应 2.0h， 以96%的产率得到d3-2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS

  摘要：

  披露的是式I的取代的磷酸二酯酶5型酶调节剂，其制备过程，药物组合物及其用途。

  公开号：

  US20080194529A1
• 作为产物：
  描述：

  methyl-d₃ methanesulfonate 、 3-正丙基吡唑-5-甲酸乙酯 反应 3.0h， 生成 d3-2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS

  摘要：

  披露的是式I的取代的磷酸二酯酶5型酶调节剂，其制备过程，药物组合物及其用途。

  公开号：

  US20080194529A1

文献信息

• 3-(DIHYDRO-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-PROPOXYBENZENESULFONAMIDE DERIVATIVES AND METHODS OF USE
  申请人：Tung Roger

  公开号：US20090270425A1

  公开（公告）日：2009-10-29

  This invention relates to novel 3-(dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5.

  本发明涉及一种新型的3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺化合物及其衍生物、药学上可接受的盐、溶剂和水合物。本发明还提供包含本发明中化合物的组合物，并且利用这些组合物治疗有益于通过给予环鸟苷酸3'，5'-单磷酸特异性磷酸二酯酶（cGMP特异性PDE）抑制剂，特别是PDE5来治疗疾病和病症的方法。
• 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
  申请人：Tung Roger

  公开号：US20090197899A1

  公开（公告）日：2009-08-06

  This invention relates to novel 3-(dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5.

  本发明涉及新型3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺化合物，它们的衍生物，药学上可接受的盐，溶剂化合物和水合物。本发明还提供包含本发明化合物的组合物以及这种组合物在治疗通过给予环鸟苷酸3'，5'-单磷酸特异性磷酸二酯酶（cGMP特异性PDE）抑制剂，特别是PDE5治疗有益的疾病和病症的方法中的使用。
• Deuterated pyrazolopyrimidinones and drugs containing said compounds
  申请人：Alken Rudolf-Giesbert

  公开号：US20050069276A1

  公开（公告）日：2005-03-31

  The invention concerns deuterated pyrazolopyrimidinones as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated pyrazolopyrimidinones for the inhibition of thrombocyte adhesion and aggregation, for the long-term increase of memory and learning functions, as well as for the treatment of cardiac and circulatory disorders, hypertonia, pulmonary hypertonia, erectile dysfunction and obstructive respiratory disorders such as, e.g., bronchial asthma. In addition, the invention discloses pharmaceutical compositions of deuterated pyrazolopyrimidinones as well as their physiological compatible salts for the inhibition of thrombocyte adhesion and aggregation, for the long-term increase of memory and learning functions, as well as for the treatment of cardiac and circulatory disorders, hypertonia, pulmonary hypertonia, erectile dysfunction and obstructive respiratory disorders such as, e.g., bronchial asthma, in addition to pharmaceutically compatible adjuvants and/or additives.